Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (6) , 2490-2496
- https://doi.org/10.1158/0008-5472.can-06-3028
Abstract
Alterations of the Wnt/β-catenin signaling pathway are positively associated with the development and progression of human cancer, including carcinoma of the prostate. To determine the role of activated Wnt/β-catenin signaling in mouse prostate carcinogenesis, we created a mouse prostate tumor model using probasin-Cre–mediated deletion of Apc. Prostate tumors induced by the deletion of Apc have elevated levels of β-catenin protein and are highly proliferative. Tumor formation is fully penetrant and follows a consistent pattern of progression. Hyperplasia is observed as early as 4.5 weeks of age, and adenocarcinoma is observed by 7 months. Continued tumor growth usually necessitated sacrifice between 12 and 15 months of age. Despite the high proliferation rate, we have not observed metastasis of these tumors to the lymph nodes or other organs. Surgical castration of 6-week-old mice inhibited tumor formation, and castration of mice with more advanced tumors resulted in the partial regression of specific prostate glands. However, significant areas of carcinoma remained 2 months postcastration, suggesting that tumors induced by Apc loss of function are capable of growth under conditions of androgen depletion. We conclude that the prostate-specific deletion of Apc and the increased expression of β-catenin associated with prostate carcinoma suggests a role for β-catenin in prostate cancer and offers an appropriate animal model to investigate the interaction of Wnt signaling with other genetic and epigenetic signals in prostate carcinogenesis. [Cancer Res 2007;67(6):2490–6]Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- High grade prostatic intraepithelial neoplasia with squamous differentiation: Figure 1Journal of Clinical Pathology, 2006
- Prevalent mutations in prostate cancerJournal of Cellular Biochemistry, 2005
- Wnt signalling and prostate cancerProstate Cancer and Prostatic Diseases, 2005
- Cystic Renal Neoplasia Following Conditional Inactivation of Apc in Mouse Renal Tubular EpitheliumPublished by Elsevier ,2005
- THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASEAnnual Review of Cell and Developmental Biology, 2004
- WNT and β-catenin signalling: diseases and therapiesNature Reviews Genetics, 2004
- Expression of Concern: Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinomaPublished by Wiley ,2004
- APC/CTNNB1 (β‐catenin) pathway alterations in human prostate cancersGenes, Chromosomes and Cancer, 2002
- Studies of neoplasia in the Min mouseBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1997
- Homozygosity for theMinallele ofApcresults in disruption of mouse development prior to gastrulationDevelopmental Dynamics, 1995